EdgeScore

MREO · Nasdaq

Mereo BioPharma Group plc: financial statements

Financially weak · see the checkFigures in USD, fiscal years

Revenue and net income

Revenue 2022: $0Net income 2022: -$42.2M2022Revenue 2023: $10.0MNet income 2023: -$29.5M2023Revenue 2024: $0Net income 2024: -$43.3M2024Revenue 2025: $500KNet income 2025: -$41.9M2025
RevenueNet income

Operating and free cash flow

Operating cash flow 2022: -$48.8MFree cash flow 2022: -$48.8M2022Operating cash flow 2023: -$21.1MFree cash flow 2023: -$21.1M2023Operating cash flow 2024: -$32.8MFree cash flow 2024: -$32.8M2024Operating cash flow 2025: -$31.0MFree cash flow 2025: -$31.0M2025
Operating cash flowFree cash flow

Margins

Operating 2023: -284.2%Operating 2025: -8021.4%Net 2023: -294.7%Net 2025: -8375.6%2022202320242025
GrossOperatingNet

Returns

ROE 2022: -82.1%ROE 2023: -58.3%ROE 2024: -70.9%ROE 2025: -102.4%ROA 2022: -54.5%ROA 2023: -44.3%ROA 2024: -56.6%ROA 2025: -91.2%2022202320242025
ROEROICROA

Income statement

USD2022202320242025Last year
Revenue$0$10.0M$0$500K
Operating income-$54.4M-$28.4M-$47.4M-$40.1M+15%
EBITDA-$54.2M-$28.2M-$47.2M-$40.0M+15%
Interest expense$4.2M$2.9M$1.4M$255K-81%
Profit before tax-$42.9M-$30.0M-$43.3M-$41.9M+3%
Income tax-$718K-$532K$0$0
Net income-$42.2M-$29.5M-$43.3M-$41.9M+3%

Cash flow

USD2022202320242025Last year
Operating cash flow-$48.8M-$21.1M-$32.8M-$31.0M+6%
Capital expenditure$13.0K$0$0$20.0K
Free cash flow-$48.8M-$21.1M-$32.8M-$31.0M+6%
Depreciation & amortization$181K$171K$143K$157K+10%

Balance sheet

USD2022202320242025Last year
Cash$68.2M$57.4M$69.8M$41.0M-41%
Current assets$75.2M$63.8M$74.8M$45.0M-40%
Total assets$77.4M$66.5M$76.4M$45.9M-40%
Current liabilities$24.4M$9.5M$13.8M$4.3M-69%
Total liabilities$26.0M$16.0M$15.4M$5.0M-68%
Shareholders' equity$51.4M$50.5M$61.0M$40.9M-33%
Net debt-$68.2M-$57.4M-$69.8M-$41.0M+41%

Ratios

2022202320242025Last year
Operating margin—-284.2%—-8021.4%
Net margin—-294.7%—-8375.6%
Return on equity-82.1%-58.3%-70.9%-102.4%
Return on assets-54.5%-44.3%-56.6%-91.2%
Interest coverage-13.0x-9.9x-34.6x-157.3x
Current ratio3.096.725.4010.46
Quick ratio3.096.725.4010.46

Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.

For information and education only. Not investment advice. Data may contain errors.